Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML
The long-term safety follow-up focuses on survivors at least three months after treatment, rather than all treated patients.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Actinium Pharmaceuticals (ATNM) announced an ASH 2026 abstract evaluating long-term safety of Actimab-A plus CLAG-M chemotherapy in relapsed or refractory acute myeloid leukemia.
The Phase 1 follow-up examines blood count recovery and potential delayed kidney and liver toxicities among patients who survived at least three months after treatment. Previously presented ASH 2022 data reported estimated one-year and two-year overall survival of 59% and 32% in patients previously treated with venetoclax, and 51% and 19% in patients with TP53-mutated disease. Actinium said the findings support further evaluation of Actimab-A as a potential treatment backbone across mutations in CD33-positive AML. The poster is scheduled for December 13, 2026.
Positive
- Minor pointPrior venetoclax-treated patients had estimated one-year and two-year overall survival of 59% and 32%, respectively.
- Minor pointTP53-mutated AML patients had estimated one-year and two-year overall survival of 51% and 19%, respectively.
- Minor point. Forward-looking: it has not happened yet and may not happen.Actinium supports further clinical evaluation of Actimab-A combinations as a potential treatment backbone across AML mutations.
Negative
- Minor pointLong-term safety analysis includes only patients surviving at least three months after treatment.
Key Figures
- One-year overall survival
- 59%
- Patients previously treated with venetoclax; previously presented at ASH 2022
- Two-year overall survival
- 32%
- Patients previously treated with venetoclax; previously presented at ASH 2022
- One-year overall survival
- 51%
- Patients with TP53-mutated AML; previously presented at ASH 2022
- Two-year overall survival
- 19%
- Patients with TP53-mutated AML; previously presented at ASH 2022
Key Terms
acute myeloid leukemia medical
overall survival medical
allogeneic hematopoietic cell transplantation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Results report the safety of combining targeted alpha therapy with CLAG-M for patients with relapsed or refractory acute myeloid leukemia
- Long-term follow-up evaluates bone marrow recovery and potential delayed kidney and liver toxicities following Actimab-A plus intensive salvage chemotherapy
- Findings support development of Actimab-A as a potential mutation-agnostic AML backbone, building on prior clinical activity following venetoclax failure and in TP53-mutated disease
The abstract presents follow-up from a Phase 1 study of Actimab-A plus CLAG-M, with a focused analysis of blood count recovery and potential delayed kidney and liver toxicities among patients who survived at least three months after treatment. These safety findings complement efficacy data previously presented at ASH 2022, which reported estimated one-year and two-year overall survival of
"These long-term safety findings support our strategy to advance Actimab-A as a potential mutation-agnostic therapeutic backbone for AML," said Sandesh Seth, Actinium's Chairman and CEO. "The previously reported clinical activity of Actimab-A plus CLAG-M, including in patients whose disease has failed venetoclax-based therapy and those with TP53 mutations, reinforces its potential to address difficult-to-treat disease. Together with the long-term safety follow-up, these observations support further clinical evaluation of Actimab-A in combination regimens, with the goal of improving outcomes and expanding treatment options for patients with resistant disease and limited therapeutic alternatives."
Actimab-A ASH 2026 Presentation Details
Abstract Title: Long-Term Safety and Tolerability after Intensive Salvage therapy with CLAG-M for Relapsed/Refractory AML
Session Title: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I
Presenting Author: Sameem Abedin, MD, Medical College of
Location: Ernest N. Morial Convention Center, Hall F
Date: Sunday, December 13, 2026
Time: 6:00 PM – 8:00 PM
About Actinium Pharmaceuticals, Inc.
Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets HER3, an antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com.
Forward-Looking Statements
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Investor Contact
Peter (PJ) Kelleher
LifeSci Advisors
pkelleher@lifesciadvisors.com
(617) 430-7579
View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-ash-2026-abstract-highlighting-long-term-results-of-actimab-a-in-combination-with-clag-m-in-relapsed-or-refractory-aml-302928605.html
SOURCE Actinium Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Actinium's ASH 2026 Actimab-A abstract evaluate?
The abstract evaluates long-term safety and tolerability of Actimab-A combined with CLAG-M intensive salvage chemotherapy in relapsed or refractory acute myeloid leukemia. The Phase 1 follow-up focuses on blood count recovery and potential delayed kidney and liver toxicities among patients surviving at least three months after treatment.